Reinventing the wheel: Nonselective phosphodiesterase inhibitors for chronic inflammatory diseases

Cyclic Nucleotide Phosphodiesterases in Health and Disease

Volumn , Issue , 2006, Pages 649-665

  Giembycz, Mark A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 52949124088     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (140)

1. Butcher, R.W., and E.W. Sutherland. 1962. Adenosine 3',5'-phosphate in biological materials. I. Purification and properties of cyclic 3',5'-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3',5'-phosphate in human urine. J Biol Chem 237:1244.
2. Soderling, S.H., S.J. Bayuga, and J.A. Beavo. 1998. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 273:15553.
3. Beavo, J.A. 1988. Multiple isozymes of cyclic nucleotide phosphodiesterase. Adv Second Messenger Phosphoprotein Res 22:1.
4. Beavo, J.A. 1995. Cyclic nucleotide phosphodiesterases: Functional implications of multiple isoforms. Physiol Rev 75:725.
5. Conti, M., and S.L. Jin. 1999. The molecular biology of cyclic nucleotide phosphodiesterases. Prog Nucleic Acid Res Mol Biol 63:1.
6. Torphy, T.J. 1998. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents. Am J Respir Crit Care Med 157:351.
7. Giembycz, M.A. 2001. Cilomilast: A second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs 10:1361.
8. Huang, Z., et al. 2001. The next generation of PDE4 inhibitors. Curr Opin Chem Biol 5:432.
9. Doherty, A.M. 1999. Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents. Curr Opin Chem Biol 3:466.
10. Souness, J.E., D. Aldous, and C. Sargent. 2000. Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors. Immunopharmacology 47:127.
11. Dyke, H.J., and J.G. Montana. 2002. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 11:1.
12. Burnouf, C., and M.P. Pruniaux. 2002. Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr Pharm Des 8:1255.
13. Houslay, M.D., P. Schafer, and K.Y. Zhang. 2005. Phosphodiesterase-4 as a therapeutic target. Drug Discov Today 10:1503.
14. Giembycz, M.A. 2000. Phosphodiesterase 4 inhibitors and the treatment ofasthma: Where are we now and where do we go from here? Drugs 59:193.
15. Duplantier, A.J., et al. 1996. Biarylcarboxylic acids and amides: Inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret. J Med Chem 39:120.
16. Souness, J.E., and S. Rao. 1997. Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. Cell Signal 9:227.
17. Compton, C.H., et al. 2001. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: A randomised, dose-ranging study. Lancet 358:265.
18. Torphy, T.J., et al. 1999. Ariflo (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: From concept to clinic. Pulm Pharmacol Ther 12:131.
19. Giembycz, M.A. 2002. Development status of second generation PDE4 inhibitors for asthma and COPD: The story so far. Monaldi Arch Chest Dis 57:48.
20. 2004. Roflumilast: APTA 2217, B9302-107, BY 217, BYK 20869. Drugs RD 5:176.
21. Rabe, K.F., et al. 2005. Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 366:563.
22. Giembycz, M.A. 2006. An update and appraisal of the cilomilast phase III clinical development programme for chronic obstuctive pulmonary disease. Br J Clin Pharmacol 62:138.
23. Lagente, V., et al. 2005. Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases. Mem Inst Oswaldo Cruz 100 Suppl 1:131.
24. Brown, W.M. 2005. Cilomilast GlaxoSmithKline. Curr Opin Investig Drugs 6:545.
25. Soto, F.J., and N.A. Hanania. 2005. Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease. Curr Opin Pulm Med 11:129.
26. Lipworth, B.J. 2005. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365:167.
27. Jeffery, P. 2005. Phosphodiesterase 4-selective inhibition: Novel therapy for the inflammation of COPD. Pulm Pharmacol Ther 18:9.
28. Gamble, E., et al. 2003. Antiinflammatory effects of the phosphodiesterase-4 inhibitor cilomilast (Ariflo) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 168:976.
29. Howell, R.E., W.T. Muehsam, and W.J. Kinnier. 1990. Mechanism for the emetic side effect of xanthine bronchodilators. Life Sci 46:563.
30. Chowdhury, B.A. 2003. Memorandum. Overview of the FDA background materials for NDA 21-573, Ariflo (cilomilast) Tablets, 15 mg, for the maintenance of lung function (FEV1) in patients with chronic obstructive lung disease (COPD). Available at: http://www.fda.gov/ohrms/dockets/ac/03/briefmg/3976B1_02_B-FDA-Tab%201.pdf
31. Losco, P.E., et al. 2004. The toxicity of SCH 351591, a novel phosphodiesterase-4 inhibitor, in Cynomolgus monkeys. Toxicol Pathol 32:295.
32. GlaxoSmithKline. 2003. SB 207499 (Ariflo, Cilomilast)-New Drugs Application (21-573). Pulmonary and Allergy Drug Products Advisory Committee. Transcript of Hearing held on 5 September 2003 at the Holiday Inn Gaithersburg, Gaithersburg, Maryland, USA. Available at: http://www.fda.gov/ohrms/dockets/ac/03/transcripts/3976T1.doc
33. Savage, C.O. 2002. The evolving pathogenesis of systemic vasculitis. Clin Med 2:458.
34. Davies, D.J. 2005. Small vessel vasculitis. Cardiovasc Pathol 14:335.
35. Mecklenburg, L., et al. 2006. Mesenteritis precedes vasculitis in the rat mesentery after subacute administration of a phosphodiesterase type 4 inhibitor. Toxicol Lett 163:54.
36. Rao, R.R., et al. 1985. Pre-clinical toxicity studies on the new nitroimidazole 1-methylsulphonyl-3-(1-methyl-5-nitroimidazole-2-yl)-2-imidazolidinone. Arzneimittelforschung 35:1692.
37. Jones, T.R., et al. 1998. Effects of a selective phosphodiesterase IV inhibitor (CDP-840) in a leukotriene-dependent non-human primate model of allergic asthma. Can J Physiol Pharmacol 76:210.
38. Ruben, Z., et al. 1989. Spontaneous disseminated panarteritis in laboratory beagle dogs in a toxicity study: A possible genetic predilection. Toxicol Pathol 17:145.
39. Bishop, S.P. 1989. Animal models of vasculitis. Toxicol Pathol 17:109.
40. Slim, R.M., et al. 2002. Effect of dexamethasone on the metabonomics profile associated with phosphodiesterase inhibitor-induced vascular lesions in rats. Toxicol Appl Pharmacol 183:108.
41. Robertson, D.G., et al. 2001. Metabonomic assessment of vasculitis in rats. Cardiovasc Toxicol 1:7.
42. Larson, J.L., et al. 1996. The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. Pharmacol Toxicol 78:44.
43. GlaxoSmithKline. 2003. SB 207499 (Ariflo, Cilomilast)-New Drugs Application (21-573). Pulmonary and Allergy Drug Products Advisory Committee. Nonclinical Findings. Available at: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3976B1_01_C-Glaxo-Nonclinical%20-Findings.pdf
44. Data Monitor. 2003. Press Release: Merck discontinues development of PDE4 inhibitor compound. Available at: http://www.datamonitor.com/~90c3cffcaf0546f7ad089c97929631c8~/companies/company/?pid=E915DFB3-6FBF-4C67-AE8F-29EB1160FC4C&nid=816AB3F2-982C-44B3-887C-3451D89A6362&type=NewsWire&article=1
45. Nyska, A., et al. 1998. Theophylline-induced mesenteric periarteritis in F344/N rats. Arch Toxicol 72:731.
46. Collins, J.J., et al. 1988. Subchronic toxicity of orally administered (gavage and dosed-feed) theophylline in Fischer 344 rats and B6C3F1 mice. Fundam Appl Toxicol 11:472.
47. Torphy, T.J., et al. 1993. Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle. J Pharmacol Exp Ther 265:1213.
48. Giembycz, M.A., and P.J. Barnes. 1991. Selective inhibition of a high affinity type IV cyclic AMP phosphodiesterase in bovine trachealis by AH 21-132. Relevance to the spasmolytic and anti-spasmogenic actions of AH 21-132 in the intact tissue. Biochem Pharmacol 42:663.
49. Torphy, T.J., et al. 1991. Role of cyclic nucleotide phosphodiesterase isozymes in intact canine trachealis. Mol Pharmacol 39:376.
50. Rybalkin, S.D., et al. 1997. Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest 100:2611.
51. Rybalkin, S.D., et al. 2002. Cyclic nucleotide phosphodiesterase 1C promotes human arterial smooth muscle cell proliferation. Circ Res 90:151.
52. Jeffery, P.K. 2001. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 164:S28.
53. Aoshiba, K., and A. Nagai. 2004. Differences in airway remodeling between asthma and chronic obstructive pulmonary disease. Clin Rev Allergy Immunol 27:35.
54. Naeije, R., and J.A. Barbera. 2001. Pulmonary hypertension associated with COPD. Crit Care 5:286.
55. Ahn, H.S., et al. 1997. Potent tetracyclic guanine inhibitors of PDE1 and PDE5 cyclic guanosine monophosphate phosphodiesterases with oral antihypertensive activity. J Med Chem 40:2196.
56. Kelly, J.J., and M.A. Giembycz. 1994. Current status of cyclic nucleotide phosphodiesterase isoenzymes. In Methylxanthines and phosphodiesterase inhibitors in the treatment of airway disease. Eds. J. Costello, and P.J. Piper, 27-80. London: Parthenon Publishing.
57. Shakur, Y., et al. 2001. Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog Nucleic Acid Res Mol Biol 66:241.
58. Meacci, E., et al. 1992. Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase. Proc Natl Acad Sci USA 89:3721.
59. Taira, M., et al. 1993. Molecular cloning of the rat adipocyte hormone-sensitive cyclic GMP-inhibited cyclic nucleotide phosphodiesterase. J Biol Chem 268:18573.
60. Myou, S., et al. 1999. Bronchodilator effect of inhaled olprinone, a phosphodiesterase 3 inhibitor, in asthmatic patients. Am J Respir Crit Care Med 160:817.
61. Bardin, P.G., et al. 1998. Effect of selective phosphodiesterase 3 inhibition on the early and late asthmatic responses to inhaled allergen. Br J Clin Pharmacol 45:387.
62. Leeman, M., et al. 1987. Reduction in pulmonary hypertension and in airway resistances by enoximone (MDL 17,043) in decompensated COPD. Chest 91:662.
63. Fujimura, M., et al. 1995. Bronchodilator and bronchoprotective effects of cilostazol in humans in vivo. Am J Respir Crit Care Med 151:222.
64. Robicsek, S.A., et al. 1991. Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem Pharmacol 42:869.
65. Giembycz, M.A., et al. 1996. Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T-lymphocytes: Role in regulating proliferation and the biosynthesis of inter-leukin-2. Br J Pharmacol 118:1945.
66. Schudt, C., H. Tenor, and A. Hatzelmann. 1995. PDE isoenzymes as targets for anti-asthma drugs. Eur Respir J 8:1179.
67. Ukena, D., et al. 1995. Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstruction. Respir Med 89:441.
68. Foster, R.W., et al. 1992. Trials of the bronchodilator activity of the isoenzyme-selective phosphodiesterase inhibitor AH 21-132 in healthy volunteers during a methacholine challenge test. Br J Clin Pharmacol 34:527.
69. Altana Press Release. 2002. ALTANA confirms its forecast for the whole year. Available at: http://www.altana.com/root/index.php?page_id-202&cms_press_id-176
70. Movsesian, M.A. 2003. PDE3 inhibition in dilated cardiomyopathy: Reasons to reconsider. J Card Fail 9:475.
71. Naeije, R. 2003. Pulmonary hypertension and right heart failure in COPD. Monaldi Arch Chest Dis 59:250.
72. Joseph, E.C. 2000. Arterial lesions induced by phosphodiesterase III (PDE III) inhibitors and DA1 agonists. Toxicol Lett 112-113:537.
73. Yamashita, K., et al. 1990. Increased external carotid artery blood flow in headache patients induced by cilostazol. Preliminary communication. Arzneimittelforschung 40:587.
74. Wilsmhurst, P.T., and M.M. Webb-Peploe. 1983. Side effects of amrinone therapy. Br Heart J 49:447.
75. Brunnee, T., et al. 1992. Bronchodilatory effect of inhaled zardaverine, a phosphodiesterase III and IV inhibitor, in patients with asthma. Eur Respir J 5:982.
76. Hatzelmann, A., et al. 1996. Enzymatic and functional aspects of dual-selective PDE3/4 inhibitors. In Phosphodiesterase inhibitors, First ed., Eds. C. Schudt, G. Dent, and K.F. Rabe, 147-160. London: Academic Press.
77. Maurice, D.H., et al. 2003. Cyclic nucleotide phosphodiesterase activity, expression, and targeting in cells of the cardiovascular system. Mol Pharmacol 64:533.
78. Edmondson, S.D., et al. 2003. Benzyl vinylogous amide substituted aryldihydropyridazinones and aryldimethylpyrazolones as potent and selective PDE3B inhibitors. Bioorg Med Chem Lett 13:3983.
79. Timms, R.M., F.U. Khaja, and G.W. Williams. 1985. Hemodynamic response to oxygen therapy in chronic obstructive pulmonary disease. Ann Intern Med 102:29.
80. Galie, N., et al. 2005. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353:2148.
81. Prasad, S., J. Wilkinson, and M.A. Gatzoulis. 2000. Sildenafil in primary pulmonary hypertension. N Engl J Med 343:1342.
82. Wilkens, H., et al. 2001. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104:1218.
83. Michelakis, E., et al. 2002. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation 105:2398.
84. Michelakis, E.D., et al. 2003. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108:2066.
85. Chockalingam, A., et al. 2005. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int JCardiol 99:91.
86. Lepore, J.J., et al. 2005. Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: Combined administration with inhaled nitric oxide. Chest 127:1647.
87. Steiner, M.K., et al. 2005. Pulmonary hypertension: Inhaled nitric oxide, sildenafil and natriuretic peptides. Curr Opin Pharmacol 5:245.
88. Sastry, B.K., et al. 2002. A study of clinical efficacy of sildenafil in patients with primary pulmonary hypertension. Indian Heart J 54:410.
89. Sastry, B.K., et al. 2004. Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 43:1149.
90. Bharani, A., et al. 2003. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Indian Heart J 55:55.
91. Zhao, L., et al. 2001. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104:424.
92. Ghofrani, H.A., et al. 2004. Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: A randomized prospective study. J Am Coll Cardiol 44:1488.
93. Gupta, M., A. Kovar, and B. Meibohm. 2005. The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction. J Clin Pharmacol 45:987.
94. Ghofrani, H.A., et al. 2002. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med136:515.
95. Michelakis, E.D. 2003. The role of the NO axis and its therapeutic implications in pulmonary arterial hypertension. Heart Fail Rev 8:5.
96. Jackson, G., et al. 1999. Effects of sildenafil citrate on human hemodynamics. Am J Cardiol 83:13C.
97. Sebkhi, A., et al. 2003. Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 107:3230.
98. Dinh-Xuan, A.T., et al. 1991. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med 324:1539.
99. Barbera, J.A., et al. 2001. Reduced expression of endothelial nitric oxide synthase in pulmonary arteries of smokers. Am J Respir Crit Care Med 164:709.
100. Wharton, J., et al. 2005. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 172:105.
101. Charan, N.B. 2001. Does sildenafil also improve breathing? Chest 120:305.
102. Toward, T.J., N. Smith, and K.J. Broadley. 2004. Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease. Am J Respir Crit Care Med 169:227.
103. Michaeli, T., et al. 1993. Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. J Biol Chem 268:12925.
104. Hetman, J.M., et al. 2000. Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase. Proc Natl Acad Sci USA 97:472.
105. Sasaki, T., et al. 2000. Identification of human PDE7B, a cAMP-specific phosphodiesterase. Biochem Biophys Res Commun 271:575.
106. Hoffmann, R., S. Abdel'Al, and P. Engels. 1998. Differential distribution of rat PDE-7 mRNA in embryonic and adult rat brain. Cell Biochem Biophys 28:103.
107. Sasaki, T., J. Kotera, and K. Omori. 2002. Novel alternative splice variants of rat phosphodiesterase 7B showing unique tissue-specific expression and phosphorylation. Biochem J 361:211.
108. Smith, S.J., et al. 2003. Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am J Physiol Lung Cell Mol Physiol 284:L279-L289.
109. Gardner, C., et al. 2000. Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase. Biochem Biophys Res Commun 272:186.
110. Glavas, N.A., et al. 2001. T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. Proc Natl Acad Sci USA 98:6319.
111. Torras-Llort, M., and F. Azorin. 2003. Functional characterization of the human phosphodiesterase 7A1 promoter. Biochem J 373:835.
112. Smith, S.J., et al. 2004. Discovery of BRL 50481 [3-(N,N-dimethylsulfonamido)-4-methylnitrobenzene), a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophage and CD8+ T-lymphocytes. Mol Pharmacol 66:1679.
113. Yang, G., et al. 2003. Phosphodiesterase 7A-deficient mice have functional T cells. J Immunol 171:6414.
114. Giembycz, M.A., and S.J. Smith. 2006. Phosphodiesterase 7 as a therapeutic target. Drugs Future 31:207.
115. Giembycz, M.A., and S.J. Smith. 2006. Phosphodiesterase 7A: A new therapeutic target for alleviating chronic inflammation? Curr Pharm Des 12:3207.
116. Li, L., C. Yee, and J.A. Beavo. 1999. CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science 283:848.
117. Stein, C.A. 2001. The experimental use of antisense oligonucleotides: A guide for the perplexed. J Clin Invest 108:641.
118. Kontny, E., et al. 2000. Rottlerin, a PKC isozyme-selective inhibitor, affects signaling events and cytokine production in human monocytes. J Leukoc Biol 67:249.
119. Hatzelmann, A., et al. 2004. Phthalazinone derivatives useful as PDE4 7 inhibitors. WO 02/085906. Altana Pharma AG.
120. Pitts, W.J., et al. 2002. Dual inhibitors of PDE7 and PDE4. WO 02/088079. Bristol-Myers Squibb.
121. Schultze-Werninghaus, G., and J. Meier-Sydow. 1982. The clinical and pharmacological history of theophylline: First report on the bronchospasmolytic action in man by S.R. Hirsch in Frankfurt (Main) 1922. Clin Allergy 12:211.
122. Barnes, P.J. 2003. Theophylline: New perspectives for an old drug. Am J Respir Crit Care Med 167:813.
123. Cortijo, J., et al. 1993. Investigation into the role of phosphodiesterase IV in bronchorelaxation, including studies with human bronchus. Br J Pharmacol 108:562.
124. Goldie, R.G., et al. 1986. In vitro responsiveness of human asthmatic bronchus to carbachol, histamine, β-adrenoceptor agonists and theophylline. Br J Clin Pharmacol 22:669.
125. Finney, M.J., J.A. Karlsson, and C.G. Persson. 1985. Effects of bronchoconstrictors and bronchodilators on a novel human small airway preparation. Br J Pharmacol 85:29.
126. Guillot, C., et al. 1984. Spontaneous and provoked resistance to isoproterenol in isolated human bronchi. J Allergy Clin Immunol 74:713.
127. Pauwels, R., et al. 1985. The effect of theophylline and enprofylline on allergen-induced bronchoconstriction. J Allergy Clin Immunol 76:583.
128. Ward, A.J., et al. 1993. Theophylline-an immunomodulatory role in asthma? Am Rev Respir Dis 147:518.
129. Mapp, C., et al. 1987. Protective effect of antiasthma drugs on late asthmatic reactions and increased airway responsiveness induced by toluene diisocyanate in sensitized subjects. Am Rev Respir Dis 136:1403.
130. Sullivan, P., et al. 1994. Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet 343:1006.
131. Jaffar, Z.H., et al. 1996. Low-dose theophylline modulates T-lymphocyte activation in allergen-challenged asthmatics. Eur Respir J 9:456.
132. Kraft, M., et al. 1996. Theophylline: Potential antiinflammatory effects in nocturnal asthma. J Allergy Clin Immunol 97:1242.
133. Lim, S., et al. 2001. Low-dose theophylline reduces eosinophilic inflammation but not exhaled nitric oxide in mild asthma. Am J Respir Crit Care Med 164:273.
134. Culpitt, S.V., et al. 2002. Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 165:1371.
135. Dent, G., and K.F. Rabe. 1996. Effects of theophylline and non-selective xanthine derivatives on PDE isoenzymes and cellular function. In Phosphodiesterase inhibitors. Eds. C. Schudt, G. Dent, and K.F. Rabe, 41-64. London: Academic Press.
136. Evans, D.J., et al. 1997. A comparison of low-dose inhaled budesonide plus theophylline and high-dose inhaled budesonide for moderate asthma. N Engl J Med 337:1412.
137. Ukena, D., et al. 1997. Comparison of addition of theophylline to inhaled steroid with doubling of the dose of inhaled steroid in asthma. Eur Respir J 10:2754.
138. Lim, S., et al. 2000. Comparison of high dose inhaled steroids, low dose inhaled steroids plus low dose theophylline, and low dose inhaled steroids alone in chronic asthma in general practice. Thorax 55:837.
139. Cosio, B.G., et al. 2004. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 200:689.
140. Ito, K., et al. 2002. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 99:8921.